Gilead’s remdesivir prequalified

News

25 April, 2022 - 19:20 (CEST)

Announcement

WHO Prequalification Unit (PQT) added the below new product to its prequalified list:

CV011 - Remdesivir - 100mg - Powder for concentrate for solution for infusion - Gilead Sciences Ireland UC - IRELAND

Featured News

Long Term Agreement for WHO Prequalification Website Maintenance and Support

UPDATE - Date of submission of proposals revised to 10 January 2025!The purpose of this Long-Term Agreement (LTA) Proposal is to identify a suitable contractor to provide support and maintenance to the WHO Prequalification Unit (PQT) website. PQT needs continued support for the 6 PQ Streams of the Unit, on its ePQS system and technical support to PQT staff.Deadline for submission of complete proposals to WHOhas been revised from 20 December 2024 to 10 January 2025 at 18:00 hours, CET time ("the Closing Date for Submission of Proposals") by email to civerav@who.intFor more information, please follow link: Long Term Agreement for WHO Prequalification Website Maintenance and SupportYou may also contact PQT directly at: prequal@who.int 

Request for Proposals: Review of cold chain equipment dossier submissions for prequalification

Please visit: https://www.ungm.org/Public/Notice/239857 

Request for Proposals (RFP): Support to the WHO Immunization Devices and Equipment Prequalification Team

The WHO Immunization Devices and Equipment Prequalification Team is seeking to enter into a contractual agreement with a successful bidder to implement the following work packages: 1.     Implementation of post market monitoring (PMM) of cold chain equipment project2.     Assessment of new cold room technologies and support to standard setting3.     Field testing of new technologies4.     Investigation of technological solutions to problems caused by unstable mains power5.     Authoring specifications and verification protocols for chemical indicators6.     IT Helpdesk support to countries implementing PMM WHO aims to select one or more Long Term Agreement (LTA) provider. The Request for Proposals (RFP) is published on the United Nations Global Market website: https://www.ungm.org/Public/Notice/234522 To access this RFP, please register to the United Nations Global Marketplace (UNGM) at Basic level. Please note that the full registration process must be completed to access the tender documents. Should you encounter difficulties, please consult registry@ungm.org. Deadline: 24 May 2024 Organisation: WHO Location: Various 

WHO to begin development of parallel recommendation and regulatory pathways; shortening the time taken for people to access health products

Ensuring access to quality-assured, safe and effective therapies is a core part of WHO’s mission. This involves two essential services: the development of recommendations on the use of important health products and, independently, their prequalification (PQ) or Emergency Use Listing (EUL). Health products include medicines, vaccines, medical devices including diagnostics and vector control products and may include other products based on future technology developments. Currently, recommendation development and PQ or EUL assessment occur sequentially. During the pandemic, WHO expedited the recommendation review and EUL of COVID-19 health products as parallel processes. This resulted in listing of the first antivirals several hours after the publication of their recommendations for use. What was an interim WHO process for the COVID-19 pandemic, will now be adopted for all products with the development of synchronized and parallel, but otherwise entirely independent processes. This will shorten time to access innovative health products in low / low-middle income countries.  Parallel processes will be triggered whenever WHO identifies the need to issue a new or revised recommendation. The target for the dual processes will be to complete both within twelve months from WHO’s initiation of the recommendation development process and formally accepting a manufacturer’s dossier for PQ or EUL assessment. The processes will conclude with a coordinated external communication of their outcome to the manufacturer and Member States.   Vitally, the integrity of the procedure will be maintained as the two processes remain fully independent and respect the confidentiality of manufacturers’ information as appropriate.  This new parallel process will improve access to essential and innovative health products and address inequities in countries that rely on WHO recommendations for the use of these products.  Links WHO PQ: Home | WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control) WHO EUL: https://www.who.int/teams/regulation-prequalification/eul    

Technical Specifications Series for WHO PQ of computer aided diagnosis of TB - for public comment (deadline 30 April 2024)

WHO Prequalification is inviting you to review the draft working document on Technical Specifications Series for submission to WHO Prequalification – Medical Device Assessment Screening and Triage of TB using Computer Aided Detection Software for Interpretation of Chest X-Ray Images (CAD for TB).   Deadline for submission of comments is 30 April, 2024 Please click this link to visit a page with more details.

Gilead’s remdesivir prequalified

Related Links